Biotech companies will be facing particular ethical challenges as their products enter the marketplace. How is the industry preparing? Ken Wilan investigates.
This is a preview of subscription content, log in via an institution to check access.
References
Brady, R.P., Manning, M., Solomon, S.L., Spivack, P.S. & Stanton, A.C. DOJ settles two major off-label cases: recent settlements highlight array of DOJ enforcement inquiries. Pharmaceutical and Biotechnology Update, published online 29 December 2005. http://www.hhlaw.com/newsstand/ pubDetail.aspx?publication=2072
Loftus, P. Former worker sues Genentech over marketing. Boston.com News, published online 11 January 2006. http://www.boston.com/news/local/massachusetts/articles/2006/01/11/ former_worker_sues_genentech_over_drug_marketing/
Herper, M. When doctors go off label. Forbes, published online 10 October 2004. http://www.forbes.com/home/sciencesandmedicine/ 2004/10/05/cx_mh_1005genentech.html
The International Business Forum's 13th Annual Biotech Investment Conference. Millbrae, California, November 2–3, 2005.
Finegold, D. et al. BioIndusty Ethics (Elsevier, Amsterdam, 2005).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/NatureBiotechnology19,991-992(01Oct2001)
https://doi.org/10.1038/NatureBiotechnology22,509-510(01May2004)
https://doi.org/10.1038/NatureBiotechnology437,932-933(13Oct2005)
Web links
Rights and permissions
About this article
Cite this article
Wilan, K., DeFrancesco, L. Finding the moral high ground. Nat Biotechnol 24, 237–239 (2006). https://doi.org/10.1038/nbt0306-237
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0306-237
- Springer Nature America, Inc.